Last reviewed · How we verify
BT5528
BT5528 is a small molecule inhibitor of the CD47/SIRPα axis.
BT5528 is a small molecule inhibitor of the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | BT5528 |
|---|---|
| Sponsor | BicycleTx Limited |
| Drug class | CD47/SIRPα inhibitor |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By blocking the interaction between CD47 and SIRPα, BT5528 aims to prevent tumor cells from evading immune surveillance. This mechanism is thought to enhance the body's immune response against cancer cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (PHASE2)
- Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BT5528 CI brief — competitive landscape report
- BT5528 updates RSS · CI watch RSS
- BicycleTx Limited portfolio CI